DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the FDC LIMITED (FDC) share price today?

FDC LIMITED (FDC) is trading at ₹420.1 on the NSE, down 0.38% on the day. Source: DocStoX.

What is the PE ratio of FDC LIMITED?

FDC LIMITED has a price-to-earnings (PE) ratio of 24.3 in the Healthcare sector.

What is the market capitalisation of FDC LIMITED?

FDC LIMITED has a market capitalisation of approximately ₹6,848 crore.

FDC LIMITED

FDC·NSE·Healthcare

₹420.10▼ -1.60 (-0.38%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹413.55

₹422.60

52W₹313

₹52850%

Open

₹422.00

High

₹422.60

Low

₹413.55

Prev Close

₹421.70

Volume

86.9K

VWAP

₹419.27

Snapshot

Key fundamentals

Market Cap

₹6,848 Cr

P/E Ratio

24.30Fair

P/B Ratio

2.84

EPS

₹17.29

Book Value

₹153.00

ROE

12.50%Average

ROCE

17.00%Decent

Dividend Yield

1.16%

Debt / Equity

0.01Low

Face Value

₹1.00

52W High

₹527.80

52W Low

₹312.95

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹174

▼ 58.5%downside

Trading at ₹420 — 58% above our estimate

BearFair valueBull

₹148₹174₹244

/100

Business quality — Solid

Growth 40Profitability 49Efficiency 23Valuation 82

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 2/9)

Strengths

Virtually debt-free balance sheet
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

13% ROE fading to 12% over ~3 yrs, on ₹153 book

₹155

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹244

Analyst target

No analyst coverage

—

Blended fair value₹174

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

24.3Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

12.5%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹6,848 Cr

P/B

2.84

EPS

₹17.29

Div Yield

1.16%

What changed

Recent changes

Foreign investors-1.0% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 24.3×

Growth

Steady

+7% rev CAGR

Profitability

Healthy

12.5% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %57.2%

Turnover₹364.15L Cr

Trades6,914

VWAP₹419.27

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.8%

+10.3%

10Y

+8.1%

Profit

+13.1%

-1.4%

10Y

+5.2%

EPS

+13.9%

-0.6%

10Y

+6.2%

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 19.8%

Watch-outs

Cons

The company has delivered a poor sales growth of 10.3% over past five years.
Company has a low return on equity of 12.8% over last 3 years.
Working capital days have increased from 68.7 days to 121 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors sold 1.00 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

70%

Promoter

Promoters

69.7%0.00

Public

22.6%+0.98

FII / FPI

1.4%-1.00

DII

6.3%+0.02

Quarterly trend

Ownership over time

Q1 FY27

Promoter69.65%

FII1.40%

DII6.31%

Public22.63%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

FDC LIMITED valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

FDC LIMITED peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare FDC LIMITED with peers

FDC LIMITED vs SUN PHARMACEUTICAL IND L FDC LIMITED vs DIVI S LABORATORIES LTD FDC LIMITED vs TORRENT PHARMACEUTICALS L FDC LIMITED vs APOLLO HOSPITALS ENTER. L FDC LIMITED vs ZYDUS LIFESCIENCES LTD FDC LIMITED vs CIPLA LTD

FDC LIMITED

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

FDC LIMITED valuation & research

FDC LIMITED peers in Healthcare

Compare FDC LIMITED with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions